Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMZN Option Income Strategy ETF vs Novartis AG — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $11.14, while Novartis AG trades at $152.53 (market cap $291.04B). The key difference: Novartis AG pays a 3.11% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and Novartis AG is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | NVS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $15.75 | $168.62 |
52-Week Low | $9.98 | $121.20 |
Market Cap | — | $291.04B |
Enterprise Value | — | $332.36B |
Dividend Yield | — | 3.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $11.24, down 3.27% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock faces critical support at $11 and resistance at $12. Recent news highlights consistent weekly dividend distributions from YieldMax ETFs, though analyst reports express concerns about NAV erosion despite the high yield strategy.
The outlook for AMZY is mixed; the bullish technical trend and high dividend yield present income opportunities, but fundamental risks include potential NAV erosion and underperformance relative to Amazon. Investors should weigh the attractive weekly distributions against the sustainability of the option income strategy and amplified downside risks highlighted by analysts.
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
